Asset
ONTUNISERTIB
AGOMAB THERAPEUTICS NV AMERICAN DEPOSITARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07118878 | phase1 | completed | 2025-08-06 | 2025-09-15 | Agomab Spain S.L.U. | A Multiple Ascending Dose Study With AGMB-129 in Healthy Participants |
| NCT05937386 | phase1 | completed | 2023-08-09 | 2023-09-06 | Agomab Spain S.L. | Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants |
| NCT07672574 | phase1 | recruiting | 2026-09-09 | 2026-09-26 | Agomab Spain S.L.U. | Human Mass Balance Study of [14C] Ontunisertib in Healthy Volunteers |
| NCT07683325 | phase2 | recruiting | 2026-10-30 | 2028-12-31 | Agomab Spain S.L.U. | NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's Disease |
| NCT06397508 | phase1 | completed | 2024-04-02 | 2024-05-08 | Agomab Spain S.L. | Relative Bioavailability and Effect of Food Study With AGMB-129 in Healthy Participants |
FDA applications (0)
This company has no applications containing this asset.